PE20181803A1 - Inhibidores de mcl-1 macrociclicos para tratar el cancer - Google Patents
Inhibidores de mcl-1 macrociclicos para tratar el cancerInfo
- Publication number
- PE20181803A1 PE20181803A1 PE2018001558A PE2018001558A PE20181803A1 PE 20181803 A1 PE20181803 A1 PE 20181803A1 PE 2018001558 A PE2018001558 A PE 2018001558A PE 2018001558 A PE2018001558 A PE 2018001558A PE 20181803 A1 PE20181803 A1 PE 20181803A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitors
- treat cancer
- mcl
- compounds
- refers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) QUE ES EL ACIDO 17-CLORO-5,13,14,22-TETRAMETIL-28-OXA-2,9-DITIA-5,6,12,13,22-PENTAAZAHEPTACICLO[27.7.1.1 4,7. 0 11,15. 0 16,21. 0 20,24. 0 30,35]OCTATRIACONTA-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-TRIDECAENO-23-CARBOXILICO, ASI COMO COMPUESTOS DE FORMULAS (II) Y (III). TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA 1 DE LEUCEMIA DE CELULAS MIELOIDES (Mcl-1) SIENDO UTILES PARA REDUCIR O INHIBIR EL CRECIMIENTO DE UN TUMOR O LA PROLIFERACION DE CELULAS CANCEROSAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181803A1 true PE20181803A1 (es) | 2018-11-19 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001558A PE20181803A1 (es) | 2016-04-22 | 2017-04-21 | Inhibidores de mcl-1 macrociclicos para tratar el cancer |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9840518B2 (es) |
| EP (1) | EP3445767B1 (es) |
| JP (1) | JP6894449B2 (es) |
| KR (1) | KR102388208B1 (es) |
| CN (1) | CN109071566B (es) |
| AR (1) | AR108301A1 (es) |
| AU (1) | AU2017252222B2 (es) |
| BR (1) | BR112018070677B1 (es) |
| CL (1) | CL2018002410A1 (es) |
| CO (1) | CO2018008759A2 (es) |
| CR (1) | CR20180499A (es) |
| CY (1) | CY1123186T1 (es) |
| DK (1) | DK3445767T3 (es) |
| DO (1) | DOP2018000222A (es) |
| EA (1) | EA036551B1 (es) |
| ES (1) | ES2791319T3 (es) |
| HR (1) | HRP20200673T1 (es) |
| HU (1) | HUE049591T2 (es) |
| IL (1) | IL262237B (es) |
| LT (1) | LT3445767T (es) |
| MA (1) | MA44721B1 (es) |
| ME (1) | ME03729B (es) |
| MX (1) | MX386103B (es) |
| NI (1) | NI201800093A (es) |
| PE (1) | PE20181803A1 (es) |
| PH (1) | PH12018502227A1 (es) |
| PL (1) | PL3445767T3 (es) |
| PT (1) | PT3445767T (es) |
| RS (1) | RS60257B1 (es) |
| SG (1) | SG11201805838UA (es) |
| SI (1) | SI3445767T1 (es) |
| SM (1) | SMT202000249T1 (es) |
| SV (1) | SV2018005742A (es) |
| TN (1) | TN2018000319A1 (es) |
| TW (1) | TWI742074B (es) |
| WO (1) | WO2017182625A1 (es) |
| ZA (1) | ZA201807766B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3013650A1 (en) | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| JP7104627B2 (ja) | 2016-02-04 | 2022-07-21 | ザ・ジョンズ・ホプキンス・ユニバーシティ | ラパグルチン（ｒａｐａｇｌｕｔｉｎｓ）、ｇｌｕｔの新規阻害剤及びその使用 |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| EA036551B1 (ru) | 2016-04-22 | 2020-11-23 | Астразенека Аб | Макроциклические ингибиторы mcl1 для лечения рака |
| JP7013389B2 (ja) | 2016-05-19 | 2022-01-31 | バイエル アクチェンゲゼルシャフト | 大環状インドール誘導体 |
| TWI781996B (zh) | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| TW201920204A (zh) * | 2017-08-15 | 2019-06-01 | 美商艾伯維有限公司 | 大環ｍｃｌ-１抑制劑以及使用方法 |
| US10676485B2 (en) | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| US11401278B2 (en) | 2017-11-17 | 2022-08-02 | The Broad Institute, Inc. | Macrocyclic indole derivatives |
| EP3710447A1 (en) * | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| US11440923B2 (en) | 2017-11-17 | 2022-09-13 | Bayer Aktiengesellschaft | Substituted macrocyclic indole derivatives |
| WO2019096909A1 (en) * | 2017-11-17 | 2019-05-23 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| EP3710448A1 (en) * | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| US11447504B2 (en) | 2017-11-17 | 2022-09-20 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| CN112533929B (zh) * | 2018-09-30 | 2022-09-16 | 福建盛迪医药有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| WO2020103864A1 (en) * | 2018-11-22 | 2020-05-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic indoles as mcl-1 inhibitors |
| EP3781575A4 (en) * | 2019-01-23 | 2021-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | MACROCYCLIC FUSION PYRRAZOLES USED AS MCL-1 INHIBITORS |
| KR20210153051A (ko) * | 2019-03-08 | 2021-12-16 | 제노 매니지먼트, 인크. | 매크로사이클릭 화합물 |
| WO2020210629A1 (en) | 2019-04-11 | 2020-10-15 | Bristol-Myers Squibb Company | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations |
| CN113574058B (zh) * | 2019-04-30 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| WO2020229974A1 (en) | 2019-05-10 | 2020-11-19 | Janssen Biotech, Inc. | Macrocyclic chelators and methods of use thereof |
| WO2020236556A1 (en) | 2019-05-17 | 2020-11-26 | The Broad Institute, Inc. | Methods of preparing macrocyclic indoles |
| WO2020236817A2 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| WO2020254471A1 (en) | 2019-06-21 | 2020-12-24 | Janssen Pharmaceutica Nv | Macrocyclic inhibitors of mcl-1 |
| ES2987630T3 (es) | 2019-07-09 | 2024-11-15 | Janssen Pharmaceutica Nv | Derivados de espirociclos macrocíclicos como inhibidores de MCL-1 |
| US20220372014A1 (en) * | 2019-10-01 | 2022-11-24 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| JP2023502692A (ja) * | 2019-11-21 | 2023-01-25 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状スルホニル誘導体 |
| US20230021562A1 (en) | 2019-11-21 | 2023-01-26 | Janssen Pharmaceutica Nv | Macrocylic indole derivatives mcl-1 inhibitors |
| BR112022012136A2 (pt) * | 2019-12-18 | 2022-08-30 | Zeno Man Inc | Compostos macrocíclicos |
| KR20220143906A (ko) | 2020-02-21 | 2022-10-25 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 거대환식 인돌 유도체 |
| CN115335384B (zh) * | 2020-03-30 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种吲哚类大环衍生物的结晶形式及其制备方法 |
| MX2022015005A (es) | 2020-05-29 | 2023-01-04 | Janssen Pharmaceutica Nv | Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1. |
| WO2021255257A1 (en) | 2020-06-19 | 2021-12-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| BR112022025631A2 (pt) | 2020-06-19 | 2023-01-17 | Janssen Pharmaceutica Nv | Derivados de 4-(pirazol-5-il)-indol macrocíclico n-ligados como inibidores de mcl-1 |
| KR20230035621A (ko) | 2020-07-08 | 2023-03-14 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서 인돌 유도체를 함유하는 마크로사이클릭 에테르 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| KR20230138444A (ko) | 2020-11-24 | 2023-10-05 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| US20240124487A1 (en) | 2020-12-17 | 2024-04-18 | Janssen Pharmaceutica Nv | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| AU2022220818A1 (en) | 2021-02-12 | 2023-09-28 | Janssen Pharmaceutica Nv | Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| KR20240019330A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항체 약물 접합체의 조합 |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| US20240401146A1 (en) | 2021-10-06 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| JP2025517435A (ja) | 2022-05-20 | 2025-06-05 | ノバルティス アーゲー | 抗新生物薬化合物の抗体－薬物コンジュゲートおよびその使用の方法 |
| TW202540185A (zh) | 2023-11-22 | 2025-10-16 | 法商施維雅藥廠 | 抗cd74抗體藥物結合物及其使用方法 |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5496876B2 (ja) | 2007-04-16 | 2014-05-21 | アッヴィ・インコーポレイテッド | ７−置換されていないインドール系Ｍｃｌ−１阻害薬 |
| EP3243814B1 (en) * | 2007-04-16 | 2018-10-17 | AbbVie Inc. | 7-substituted indole as mcl-1 inhibitors |
| NZ594019A (en) * | 2008-12-22 | 2013-08-30 | Cubist Pharm Inc | Novel antibacterial agents for the treatment of gram positive infections |
| KR20120098908A (ko) * | 2009-12-23 | 2012-09-05 | 아이언우드 파마슈티컬스, 인코포레이티드 | Ｃｒｔｈ２ 조절제 |
| SG11201400681UA (en) * | 2011-05-19 | 2014-08-28 | Ct Nac De Investigaciones Oncológicas Cnio | Macrocyclic compounds as protein kinase inhibitors |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| EP3038618B1 (en) | 2013-08-28 | 2020-10-14 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| US9944656B2 (en) * | 2014-02-12 | 2018-04-17 | VIIV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| JP6757312B2 (ja) | 2014-03-27 | 2020-09-16 | ヴァンダービルト ユニバーシティー | 置換インドールｍｃｌ−１阻害剤 |
| CU24399B1 (es) * | 2014-04-11 | 2019-04-04 | Bayer Pharma AG | Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| EA036551B1 (ru) | 2016-04-22 | 2020-11-23 | Астразенека Аб | Макроциклические ингибиторы mcl1 для лечения рака |
-
2017
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 SM SM20200249T patent/SMT202000249T1/it unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en not_active Ceased
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es active IP Right Grant
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active Active
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 MX MX2018012711A patent/MX386103B/es unknown
- 2017-04-21 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181803A1 (es) | Inhibidores de mcl-1 macrociclicos para tratar el cancer | |
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
| MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| CU20190086A7 (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados útiles como inhibidores de lats | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| CL2018002516A1 (es) | Inhibidores de mcl-1 indólicos sustituidos. | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| MX2018007267A (es) | Compuestos utiles como inhibidores de cinasa. | |
| EA201690584A1 (ru) | Пестициды на основе замещенного гетероциклом бициклического азола | |
| BR112018007381A2 (pt) | compostos úteis como imunomoduladores | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| CU20110052A7 (es) | Compuestos orgánicos | |
| CL2015001649A1 (es) | Dispersion solida fisicamente estable del acido 4-{[(2r,3s,4r,5s)-4-(4-cloro-2-fluorofenil)-4-ciano-5-(2,2-dimetilpropil)-pirrolidin-2-carbonil]-amino}-3-metoxibenzoico; formulacion solida; metodo de preparacion; preparacion farmaceutica; uso para tratar el cancer, en particular leucemia mieloide aguda o cancer de prostata. | |
| CU24385B1 (es) | Compuestos éteres de arilo útiles para tratar cancer de célula renal | |
| CL2017001336A1 (es) | Nuevos aminoácidos ester fosforamidatos 2' y/o 5', 3' deoxiadenosina derivativos como compuestos anticancerígenos | |
| MX374513B (es) | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. | |
| CU20150053A7 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| ECSP088536A (es) | DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| CO2018005639A2 (es) | Sililfenoxiheterociclos trisustituidos y análogos | |
| PE20210002A1 (es) | Sales de derivados de pirrolotriazina utiles como inhibidores tam | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos |